Properties (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:age |
12 years and older
|
| gptkbp:CEO |
gptkb:Stéphane_Bancel
|
| gptkbp:clinicalTrials |
30,000
Phase 3 for COVID-19 vaccine COVID-19_vaccine_trials |
| gptkbp:collaborations |
gptkb:AstraZeneca
|
| gptkbp:commissioningDate |
December 18, 2020
|
| gptkbp:diseaseResistance |
intramuscular injection
94.1% against symptomatic COVID-19 |
| gptkbp:distribution |
gptkb:COVAX
UNICEF various governments private sector partners GAVI |
| gptkbp:dosageForm |
two doses
|
| gptkbp:emergencyServices |
gptkb:U.S._FDA
|
| gptkbp:founded |
2010
|
| gptkbp:founder |
Noubar Afeyan
|
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Moderna
|
| gptkbp:impact |
gptkb:Spikevax
global vaccination efforts reduced hospitalization rates contributed to herd immunity public health response to COVID-19 reduced severe disease cases |
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:market |
$100 billion (2021)
|
| gptkbp:notable_player |
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency mRNA vaccine global fatigue headache muscle pain nausea fever joint pain chills lipid nanoparticles lymphadenopathy -20°C for up to 6 months redness at injection site swelling at injection site 2-8°C for 30 days |
| gptkbp:notableEvent |
mRNA-1273
|
| gptkbp:partnerships |
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:National_Institutes_of_Health |
| gptkbp:research |
Tal Zaks
|
| gptkbp:research_focus |
cancer
autoimmune diseases infectious diseases |
| gptkbp:revenue |
$18.5 billion (2021)
|
| gptkbp:scientificName |
gptkb:Spikevax
|
| gptkbp:stockExchange |
gptkb:NASDAQ
MRNA |
| gptkbp:technology |
messenger_RNA_(mRNA)_technology
|